Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Penumbra, Inc. Common Stock (NY:PEN)

255.00 +1.80 (+0.71%)
Streaming Delayed Price Updated: 3:30 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
CEO And President Of Penumbra Trades $4.18 Million In Company Stock
Adam Elsesser, CEO And President at Penumbra (NYSE:PEN), made a large buy and sell of company shares on September 13, according to a new SEC filing. What Happened: A Form 4 filing... 
Via Benzinga
Topics Regulatory Compliance
Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2021
Upgrades For Signet Jewelers Ltd (NYSE: 
Via Benzinga
Penumbra Stock Registers A Healthy RS Rating
Penumbra shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Penumbra, Inc. Investors With Losses to Inquire About Class Action Investigation – PEN
From The Rosen Law Firm, P.A.
Via Business Wire
Penumbra: Q2 Earnings Insights
Shares of Penumbra (NYSE:PEN) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 170.00% over the past year to $0.... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Penumbra: Q1 Earnings Insights
Shares of Penumbra (NYSE:PEN) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 0.00% over the past year... 
Via Benzinga
Penumbra Q2 Earnings Beat Estimates; Raises FY21 Sales Outlook
Penumbra Inc (NYSE: PEN) reported Q2 sales of $184.3 million, an increase of 75.3% Y/Y, or 72.7% on a constant currency basis, beating the consensus of $170.76 million... 
Via Benzinga
Topics Earnings
Penumbra Introduces REAL® i-Series™, Expanding REAL Immersive System to Support Broad Range of Care Providers and Mental Health Professionals
From Penumbra, Inc.
Via Business Wire
Penumbra, inc (PEN) Q2 2021 Earnings Call Transcript
PEN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Penumbra Receives FDA Clearance for RED 62 Reperfusion Catheter, Enabling Physicians to Address Broad Range of Stroke Patients
From Penumbra, Inc.
Via Business Wire
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021
Upgrades According to Argus Research, the prior rating for Diageo PLC (NYSE:DEO) was changed from Hold to Buy. The current stock performance of Diageo shows a 52-week-high... 
Via Benzinga
NYSE: PEN Long Term Investor Notice: Investigation of Potential Wrongdoing at Penumbra, Inc.
San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of current long term investors in Penumbra, Inc. (NYSE: PEN) shares over possible breaches of fiduciary duty by certain officers... 
Via SBWire
Topics Death Lawsuit
Penumbra Inc (PEN) Q1 2021 Earnings Call Transcript
PEN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
Wednesday's morning session saw 275 companies set new 52-week highs. Noteworthy Mentions: Home Depot (NYSE:HD) was the largest firm on a market cap basis to set... 
Via Benzinga
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
Via Benzinga
This Medical Device Company Just Got a Big Boost
If you like good news and support from experts, this one's for you. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.